A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures. A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience ...
A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of canna ...
Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Patients Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol OralSolution ...
An Open-Label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared with Standard of Care Antiseizure Medication, in Patients Age 1 Month to Less than 12 Months of Age with Tuberous Sclerosis Complex who Experience Inadequately-Controlled SeizuresP/0047/2020P/0350/2020P/0033/2021 An Open-Label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of ...
Trade Name: Cannabidiol OralSolution,isknownasEpidyolex100mg/mLoral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. Product Name: Cannabidiol (CBD) Product Code: GWP42003-P Trade Name: Cannabidiol OralSolution,isknownasEpidyolex100mg/mLoralsolution and isthe approv ...